Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5-(1,1-dimethylethyl)salicylic acid, also known as TBSA, is a salicylic acid derivative that features an additional tert-butyl group attached to the salicylic acid structure. This modification enhances its stability and solubility in various formulations, making it a versatile ingredient in skincare and pharmaceutical products.

16094-31-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 16094-31-8 Structure
  • Basic information

    1. Product Name: 5-(1,1-dimethylethyl)salicylic acid
    2. Synonyms: 5-(1,1-dimethylethyl)salicylic acid;5-(1,1-DIMETHYLETHYL)-2-HYDROXY-BENZOIC ACID;2-Hydroxy-5-tert-butylbenzoic acid;5-tert-Butylsalicylic acid
    3. CAS NO:16094-31-8
    4. Molecular Formula: C11H14O3
    5. Molecular Weight: 194.22706
    6. EINECS: 240-258-3
    7. Product Categories: N/A
    8. Mol File: 16094-31-8.mol
  • Chemical Properties

    1. Melting Point: 151 °C
    2. Boiling Point: 324.4°Cat760mmHg
    3. Flash Point: 164.2°C
    4. Appearance: /
    5. Density: 1.162g/cm3
    6. Vapor Pressure: 0.000101mmHg at 25°C
    7. Refractive Index: 1.552
    8. Storage Temp.: Inert atmosphere,Room Temperature
    9. Solubility: N/A
    10. PKA: 3.34±0.10(Predicted)
    11. CAS DataBase Reference: 5-(1,1-dimethylethyl)salicylic acid(CAS DataBase Reference)
    12. NIST Chemistry Reference: 5-(1,1-dimethylethyl)salicylic acid(16094-31-8)
    13. EPA Substance Registry System: 5-(1,1-dimethylethyl)salicylic acid(16094-31-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 16094-31-8(Hazardous Substances Data)

16094-31-8 Usage

Uses

Used in Cosmetic Industry:
5-(1,1-dimethylethyl)salicylic acid is used as an active ingredient for its acne-treating properties, as it helps unclog pores and improve skin texture. Its anti-inflammatory and exfoliating effects make it a popular choice in skincare formulations.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, TBSA is utilized for its potential anti-aging and antioxidant effects, contributing to the development of treatments that address skin aging and oxidative stress.
Used in Skincare Formulations:
5-(1,1-dimethylethyl)salicylic acid is used as a key component in various skincare products, such as cleansers, toners, and serums, for its ability to enhance skin clarity and reduce the appearance of blemishes.

Check Digit Verification of cas no

The CAS Registry Mumber 16094-31-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,0,9 and 4 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 16094-31:
(7*1)+(6*6)+(5*0)+(4*9)+(3*4)+(2*3)+(1*1)=98
98 % 10 = 8
So 16094-31-8 is a valid CAS Registry Number.
InChI:InChI=1/C11H14O3/c1-11(2,3)7-4-5-9(12)8(6-7)10(13)14/h4-6,12H,1-3H3,(H,13,14)

16094-31-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-tert-butyl-2-hydroxybenzoic acid

1.2 Other means of identification

Product number -
Other names 6-Oxy-3-tert.-butyl-benzol-carbonsaeure-(1)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16094-31-8 SDS

16094-31-8Relevant articles and documents

PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

-

Paragraph 00278-00279, (2019/06/17)

The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

General method for the synthesis of salicylic acids from phenols through palladium-catalyzed silanol-directed C-H carboxylation

Wang, Yang,Gevorgyan, Vladimir

, p. 2255 - 2259 (2015/02/19)

A silanol-directed, palladium-catalyzed C-H carboxylation reaction of phenols to give salicylic acids has been developed. This method features high efficiency and selectivity, and excellent functional-group tolerance. The generality of this method was demonstrated by the carboxylation of estrone and by the synthesis of an unsymmetrically o,o′-disubstituted phenolic compound through two sequential C-H functionalization processes.

Synthesis and characterization of iron trisphenolate complexes with hydrogen-bonding cavities

Adelhardt, Mario,Chalkley, Matthew J.,Heinemann, Frank W.,Sutter, Joerg,Scheurer, Andreas,Meyer, Karsten

supporting information, p. 2763 - 2765 (2014/04/03)

A new family of C3-symmetric ligands, featuring phenolate donors and a secondary coordination sphere, have been synthesized. We report the synthesis and subsequent coordination chemistry of these new tripodal N-anchored tris(phenolate) chelates, [tris(5-tert-butyl-3-N-carboxamide-2-hydroxybenzyl) amines] (H3RSalAmi), to iron(II), iron(III), and zinc(II). These electron-rich complexes have intramolecular hydrogen bonds, and therefore the potential to stabilize biologically relevant substrates in small-molecule activation chemistry.

THERMOCHROMIC COMPOSITIONS FROM TRISUBSTITUTED PYRIDINE LEUCO DYES

-

Paragraph 0041, (2013/04/13)

A thermochromic leuco dye composition contains a leuco dye moiety including one or more tri-aryl substituted pyridines, a UVA developer moiety including at least one UVA developer selected from the group consisting of salicylic acid and derivatives thereof, and biphenyls and derivatives thereof, and a carrier selected from the group consisting of a fatty ester, fatty alcohol, fatty amide, and combinations thereof.

The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex

Kohrt, Jeffrey T.,Filipski, Kevin J.,Cody, Wayne L.,Cai, Cuiman,Dudley, Danette A.,Van Huis, Chad A.,Willardsen, J. Adam,Rapundalo, Stephen T.,Saiya-Cork, Kamlai,Leadley, Robert J.,Narasimhan, Lakshmi,Zhang, Erli,Whitlow, Marc,Adler, Marc,McLean, Kirk,Chou, Yuo-Ling,McKnight, Cecile,Arnaiz, Damian O.,Shaw, Kenneth J.,Light, David R.,Edmunds, Jeremy J.

, p. 4752 - 4756 (2007/10/03)

The activated Factor VII/tissue factor complex (FVIIa/TF) plays a key role in the formation of blood clots. Inhibition of this complex may lead to new antithrombotic drugs. An X-ray crystal structure of a fluoropyridine-based FVIIa/TF inhibitor bound in the active site of the enzyme complex suggested that incorporation of substitution at the 5-position of the hydroxybenzoic acid side chain could lead to the formation of more potent inhibitors through interactions with the S1′/S2′ pocket.

NF-KB ACTIVATION INHIBITORS

-

Page/Page column 74, (2008/06/13)

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

THERAPEUTIC AGENT FOR CANCER

-

Page/Page column 74, (2010/02/11)

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

-

Page/Page column 73, (2010/02/12)

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

O-SUBSTITUTED HYDROXYARYL DERIVATIVES

-

Page/Page column 91, (2008/06/13)

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), "A" represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C1 to C6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, "E" represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16094-31-8